Today: 19 May 2026
Vertiv stock jumps 24% after earnings as VRT flags record orders and upbeat 2026 view
11 February 2026
2 mins read

Vertiv stock jumps 24% after earnings as VRT flags record orders and upbeat 2026 view

New York, Feb 11, 2026, 17:21 EST — After-hours

  • Vertiv shares jumped roughly 24% in late trading after the company posted its quarterly numbers and raised its outlook for 2026.
  • Orders jumped, pushing the backlog up to $15 billion as data center demand piled on.
  • Investors now look to see if that order momentum can stick around for the March quarter.

Shares of Vertiv Holdings Co surged roughly 24.4% to $248.51 in Wednesday’s after-hours session, building on a strong rally as the data center power-and-cooling supplier posted its quarterly numbers and delivered an upbeat outlook for 2026.

Vertiv’s status as a bellwether is turning heads—its power and thermal management systems are the backbone for artificial intelligence data centers, critical infrastructure that has to be in place before the chips have a chance to run.

Order growth has become the metric investors are watching most closely. Now, the focus shifts: was this quarter a true inflection point, or just a blip that disappears while customers work through their existing capacity?

Vertiv posted a 23% jump in fourth-quarter net sales, hitting $2.88 billion. GAAP diluted earnings landed at $1.14 per share; after adjustments, EPS came in at $1.36. Organic orders soared 252% year-over-year, pushing the backlog to $15.0 billion and putting the book-to-bill at roughly 2.9x. Looking ahead to 2026, Vertiv projects net sales between $13.25 billion and $13.75 billion, with adjusted diluted EPS targeted at $5.97 to $6.07. For the first quarter, the company expects adjusted EPS between $0.95 and $1.01.

Book-to-bill—a ratio of orders to revenue—tells a quick story: a number over 1 signals demand is outpacing shipments. Traders typically see a spike as evidence that the order pipeline is building up, faster than factories are able to work through it.

The company’s GAAP results fell short of what analysts were looking for this quarter, with numbers missing the mark, Investing.com reported. But management’s guidance for 2026 came in ahead of consensus. Sometimes that’s all it takes — weaker-than-hoped earnings, but an outlook for next year that tops the Street, can be enough to move a stock higher if investors are zeroed in on what’s coming, not what just happened.

Executive chairman Dave Cote didn’t mince words on the earnings call: “We ain’t done yet.” CEO Giordano Albertazzi, for his part, told investors he’d “never been more excited about Vertiv’s future.” Tariffs remain a factor, but CFO Craig Chamberlin signaled confidence, noting the company expects to have “materially offset” the negative margin impact from tariffs “as of the first quarter” on an exit-rate basis. Investing.com

Shares of Eaton climbed around 4.9% in late trading, while Hubbell added roughly 2.5%. Trane Technologies was up about 2.4% as well. All three supply electrical equipment for data centers.

But there’s a risk here. Orders don’t always come in smoothly; big-ticket deals might get delayed, and such a rapid backlog build could put cancellations and delivery schedules under the microscope—particularly if hyperscalers start dialing back on spending or postponing shipments.

Vertiv submitted its earnings release through a Form 8-K, a regulatory filing showed. The company also said it will make presentation materials related to the results available.

Vertiv’s investor conference, set for May 19-20 in Greenville, South Carolina, is the next big milestone. Investors want clarity on capacity plans, backlog conversion, and how management sees things playing out after this quarter’s spike in orders.

Stock Market Today

  • ABM Industries Provides Strong Dividend Yield and Attractive Valuation
    May 19, 2026, 5:13 AM EDT. ABM Industries (NYSE:ABM) presents a sustainable 2.93% dividend yield supported by a healthy 42% payout ratio, signaling potential for dividend growth. The company maintains a robust balance sheet and trades at a low valuation, making it appealing to income-focused investors seeking value stocks. This combination of steady income and growth prospects underscores ABM's appeal in the current market.

Latest articles

Evolution Stock Is Jumping—The €2 Billion Reason Investors Are Watching

Evolution Stock Is Jumping—The €2 Billion Reason Investors Are Watching

19 May 2026
Evolution AB shares surged 9% in Stockholm after the company announced a €2 billion share buyback, one of Sweden’s largest. The buyback starts immediately and may run until the 2027 annual meeting, capped at 10% of shares. The OMXS30 index rose just 0.75% in comparison. Evolution also secured a €300 million revolving credit facility from J.P. Morgan SE and Citibank Europe.
NextEra shares dip after $66.8B Dominion deal—What’s on traders’ radar now

NextEra shares dip after $66.8B Dominion deal—What’s on traders’ radar now

19 May 2026
NextEra Energy shares fell 4.6% to $89.04 late Monday after announcing a $66.8 billion stock-led merger with Dominion Energy, whose shares rose 9.4% to $67.56. The deal would create one of the world’s largest electric utilities, serving about 10 million customer accounts and owning 110 gigawatts of generation across four states.
Costco Stock Just Hit a High—Here’s the Next Thing Traders Are Watching

Costco Stock Just Hit a High—Here’s the Next Thing Traders Are Watching

19 May 2026
Costco shares closed Monday up 2.62% at $1,076.47, marking a fifth straight gain and outpacing Walmart and Target. April net sales rose 13% to $23.92 billion, with comparable sales up 11.6%. The company will report fiscal third-quarter earnings on May 28. Analysts’ average price target is $1,072.91, just below Monday’s close.

Popular

Regeneron stock sinks after cancer trial miss prompts selloff

Regeneron stock sinks after cancer trial miss prompts selloff

19 May 2026
Regeneron Pharmaceuticals shares fell 9.8% to $629.68 Monday after its late-stage melanoma drug trial with fianlimab failed to meet the main goal. The study did not show a statistically significant benefit over Merck’s Keytruda. At least 10 brokerages cut price targets. The decline outpaced broader market losses, with the Nasdaq down 0.5%.
Accenture stock drops as CEO share-sale filing and $1.4 billion contract protest hit tape
Previous Story

Accenture stock drops as CEO share-sale filing and $1.4 billion contract protest hit tape

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Next Story

Stock Market Today 12.02.2026

Go toTop